We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




First-of-Its-Kind Technology Repairs and Regenerates Heart Muscle Cells

By HospiMedica International staff writers
Posted on 17 Jun 2022
Print article
Image: A groundbreaking findings could become a powerful clinical strategy for treating heart disease (Photo courtesy of University of Houston)
Image: A groundbreaking findings could become a powerful clinical strategy for treating heart disease (Photo courtesy of University of Houston)

A first-of-its-kind technology not only repairs heart muscle cells in mice but also regenerates them following a heart attack, or myocardial infarction as it is medically known. The groundbreaking finding has the potential to become a powerful clinical strategy for treating heart disease in humans.

The new technology developed by a team of researchers at the University of Houston (Houston, TX, USA) uses synthetic messenger ribonucleic acid (mRNA) to deliver mutated transcription factors - proteins that control the conversion of DNA into RNA - to mouse hearts. The researchers demonstrated that two mutated transcription factors, Stemin and YAP5SA, work in tandem to increase the replication of cardiomyocytes, or heart muscle cells, isolated from mouse hearts. These experiments were conducted in vitro on tissue culture dishes.

Stemin turns on stem cell-like properties from cardiomyocytes and played a crucial role in the experiments, with the transcription factor being a “game changer.” Meanwhile, YAP5SA works by promoting organ growth that causes the myocytes to replicate even more. In a separate finding, the team has reported that Stemin and YAP5SA repaired damaged mouse hearts in vivo. Notably, myocyte nuclei replicated at least 15-fold in 24 hours following heart injections that delivered those transcription factors.

An added benefit of using synthetic mRNA, according to the researchers, is that it disappears in a few days as opposed to viral delivery. Gene therapies delivered to cells by viral vectors raise several biosafety concerns because they cannot be easily stopped. mRNA-based delivery, on the other hand, turns over quickly and disappears. The findings are especially important because less than 1% of adult cardiac muscle cells can regenerate. When there is a heart attack and heart muscle cells die, the contracting ability of the heart can be lost.

“No one has been able to do this to this extent and we think it could become a possible treatment for humans,” said Robert Schwartz at the UH College of Natural Sciences and Mathematics who led the study. “When both transcription factors were injected into infarcted adult mouse hearts, the results were stunning. The lab found cardiac myocytes multiplied quickly within a day, while hearts over the next month were repaired to near normal cardiac pumping function with little scarring.”

“What we are trying to do is dedifferentiate the cardiomyocyte into a more stem cell-like state so that they can regenerate and proliferate,” said recent Ph.D graduate Siyu Xiao. “This is a huge study in heart regeneration, especially given the smart strategy of using mRNA to deliver Stemin and YAP5SA.”

Related Links:
University of Houston 

Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Infant Blood Draw Station
Infant Blood Draw Station

Print article

Channels

Surgical Techniques

view channel
Image: LUMISIGHT and Lumicell DVS offer 84% diagnostic accuracy in detecting residual cancer (Photo courtesy of Lumicell)

Cutting-Edge Imaging Platform Detects Residual Breast Cancer Missed During Lumpectomy Surgery

Breast cancer is becoming increasingly common, with statistics indicating that 1 in 8 women will develop the disease in their lifetime. Lumpectomy remains the predominant surgical intervention for treating... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.